Thymosin Alpha-1
Research OnlyAlso known as: Ta1, Thymalfasin, Zadaxin, TMSB1
A 28-amino acid immunomodulatory peptide approved in over 35 countries including China and Italy for hepatitis B/C, cancer adjuvant therapy, and immunodeficiency. Extensive human clinical trial data spanning decades with strong evidence for immune enhancement.
Research Statistics
Approved in 35+ countries (Zadaxin/thymalfasin) for hepatitis B/C and cancer immunotherapy. Substantial human trial body including RCTs across Asia, Europe, and Middle East. TLR9 and dendritic cell activation mechanisms are well-characterized through multiple independent research groups globally.
Research Dossier
Overview
What is Thymosin Alpha-1 and what does the research say?
Mechanism of Action
Thymosin alpha-1 is a pleiotropic immunomodulator that enhances both innate and adaptive immunity through multiple pathways.
How It Works (Simplified)
Thymosin alpha-1 acts as an “immune training officer” that enhances multiple arms of the immune system:
Promotes T-cell maturation via TLR signaling on dendritic cells, helping immature T-cells develop into functional soldiers that recognize and attack pathogens and cancer.
Increases MHC class II expression and antigen presentation, making dendritic cells more effective at identifying threats and alerting the immune system.
Increases IL-2, IL-12, and IFN-gamma while modulating inflammatory cytokines - providing immune enhancement without hyperactivation.
Boosts natural killer cell proliferation and cytotoxic activity, enhancing the innate immune system’s rapid response to infected or cancerous cells.
Scientific Pathways
TLR2/TLR9 Pathway (T-Cell Activation)
Thymosin Alpha-1 → TLR2/TLR9 binding → MyD88 → NF-kB/MAPK → T-cell maturation
↓
Enhanced immune responseCytokine Network Modulation (Immune Enhancement)
Thymosin Alpha-1 → IL-2/IL-12/IFN-gamma upregulation → Antiviral/antitumor immunityKey Research: Romani L et al. (2004) identified TLR2/TLR9 signaling as the primary mechanism for dendritic cell activation by thymosin alpha-1. PMID:15308104
Important Limitations
- Not FDA-approved despite extensive clinical data and 35+ country approvals
- Most large trials are manufacturer-sponsored (SciClone Pharmaceuticals)
- Requires injection administration (subcutaneous, typically twice weekly)
- Effects depend on functional immune system capacity
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on clinical trials: Initial immune system modulation begins. T-cell maturation and dendritic cell activation observed. In hepatitis trials, immune markers begin to change within first 2 weeks.
Immune enhancement effects become more pronounced. Clinical trials showed increased CD4+ T-cell counts and improved cytokine profiles. In hepatitis B trials, viral load reduction may begin.
Studies show sustained immune enhancement with continued administration. Hepatitis B/C trials demonstrated viral response improvements over 24-52 weeks of treatment.
Long-term studies in hepatitis and cancer adjuvant therapy show maintained immunomodulatory effects. In countries where approved, treatment courses of 6-12 months are common.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Thymosin Alpha-1 product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Thymosin Alpha-1 with other peptides. Based on published research and mechanistic considerations.
LL-37
SynergisticBoth enhance innate immunity through complementary mechanisms - Ta1 via T-cell and dendritic cell activation, LL-37 via direct antimicrobial effects.
TB-500
CompatibleDespite both being thymosin-derived, they have distinct functions - Ta1 is immunomodulatory while TB-500 focuses on tissue repair via actin regulation.
BPC-157
CompatibleImmune enhancement from Ta1 may support tissue healing processes promoted by BPC-157, potentially beneficial in infection-prone wound scenarios.
Epithalon
CompatibleBoth developed by Russian researchers for different anti-aging targets - Ta1 for immune restoration, epithalon for telomere maintenance.
Selank
CompatibleBoth have immunomodulatory components - Ta1 as primary function, Selank as secondary effect from tuftsin backbone.
GHK-Cu
CompatibleTa1's immune support may enhance wound healing environments where GHK-Cu promotes collagen synthesis and tissue regeneration.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Thymosin Alpha-1
Thymosin Alpha-1 Calculators
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.